What are the clinical features and common triggers of cholinergic crisis in a child with congenital myasthenic syndrome treated with pyridostigmine?

Cholinergic Crisis in Congenital Myasthenic Syndrome: Clinical Features and Triggers

Cholinergic crisis in a child with congenital myasthenic syndrome presents with progressive muscle weakness (paradoxically worsening despite anticholinesterase therapy), respiratory failure, excessive secretions, miosis, bradycardia, and gastrointestinal symptoms—triggered primarily by pyridostigmine overdosage, which can occur even at standard doses in the presence of renal impairment, significant weight loss, or severe hypoalbuminemia.

Clinical Features of Cholinergic Crisis

The hallmark presentation includes:

Muscarinic Signs (Most Prominent)

• Profuse secretions (salivation, bronchorrhea, lacrimation)
• Marked miosis (pinpoint pupils)
• Severe bradycardia and hypotension
• Gastrointestinal hypermotility (diarrhea, abdominal cramping, nausea)
• Diaphoresis and urinary incontinence 1, 2

Nicotinic Signs

• Paradoxical worsening muscle weakness despite being on anticholinesterase therapy
• Respiratory muscle involvement leading to hypercapnia and hypoxemia
• Fasciculations and muscle cramps 1, 2

Life-Threatening Complications

• Respiratory failure requiring mechanical ventilation
• Severe hypercapnia (as documented with extreme elevations in arterial blood gas analysis)
• Loss of consciousness
• Markedly depressed serum cholinesterase levels 2

Critical Diagnostic Challenge

The most dangerous pitfall is distinguishing cholinergic crisis from myasthenic crisis, as both present with severe muscle weakness 1. The key differentiating features are:

• Cholinergic crisis: Excessive muscarinic signs (secretions, miosis, bradycardia) + weakness worsening after pyridostigmine doses
• Myasthenic crisis: Minimal muscarinic signs + weakness from disease progression

The FDA label explicitly warns that "overdosage of pyridostigmine bromide may result in cholinergic crisis, a state characterized by increasing muscle weakness which, through involvement of the muscles of respiration, may lead to death" 1.

Common Triggers in Children with CMS

Primary Trigger: Pyridostigmine Accumulation

Even standard therapeutic doses can precipitate crisis when:

1. Renal impairment exists (pyridostigmine is renally excreted) 2
2. Significant weight loss occurs (altering drug distribution and effective dosing) 2
3. Severe hypoalbuminemia is present (increasing free drug fraction) 2
4. Dose escalation without adequate monitoring 1

Secondary Considerations

• Intercurrent infections increasing anticholinesterase requirements, leading to inadvertent overdosing
• Masking of early overdosage signs with concurrent atropine use for gastrointestinal side effects 1
• Failure to adjust doses during acute illness or metabolic stress

Management Algorithm

When cholinergic crisis is suspected:

1. Immediately discontinue all anticholinesterase medications 1
2. Administer atropine (bolus followed by continuous infusion for severe cases) 1, 2
3. Secure airway and provide mechanical ventilation as respiratory failure is the primary cause of mortality 2
4. Consider continuous hemodiafiltration in cases with renal impairment to enhance drug clearance 2
5. Monitor serum cholinesterase levels (markedly depressed levels confirm diagnosis) 2

Special Considerations in CMS Subtypes

The response to pyridostigmine varies significantly by genetic subtype. CHRNE mutations (most common at 42.9%) typically show good response to pyridostigmine 3, making these patients particularly vulnerable to overdosage. In contrast, AGRN-related CMS may be ineffective or poorly responsive to cholinesterase inhibitors 4, reducing cholinergic crisis risk in this subtype.

PREPL deficiency and DPAGT1-related limb-girdle CMS show variable or diminishing responses over time 5, 6, requiring careful dose titration and monitoring for signs of accumulation rather than therapeutic benefit.

Prevention Strategy

• Adjust pyridostigmine doses based on weight changes, renal function, and albumin levels
• Avoid using atropine to mask gastrointestinal side effects, as this obscures early warning signs of overdosage 1
• Maintain high clinical suspicion in any child with CMS showing paradoxical weakness worsening
• Consider edrophonium testing when differentiation from myasthenic crisis is unclear 1